Phospholipase A 2 is an inflammatory predictor in Cardiovascular Diseases: Is there any spacious room to prove the causation?

Phospholipase A 2 is an inflammatory predictor in Cardiovascular Diseases: Is there any spacious room to prove the causation? Curr Cardiol Rev. 2019 May 31;: Authors: Santoso A, Heriansyah T, Rochman S Abstract Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is an enzyme family of phospholipase A 2 produced by the inflammatory cell in atherosclerotic plaque. It is transported in the circulation, attached mainly to low-density lipoprotein-cholesterol (LDL-C). It hydrolyzes glycerophospholipids particularly fatty acids at the sn-2 position and produces numerous bioactive lipids; and leads to endothelial dysfunction, atherosclerotic plaque inflammation, and development of the necrotic core in plaques. There are two kinds of phospholipase A 2 , namely: secretory phospholipase A 2 (sPLA 2 ) and Lp-PLA 2 . They are deemed as evolving predictors of cardiovascular disease (CVD) risk in hospital- and population-based studies, including healthy subjects, acute coronary syndromes (ACS) and patients with CVD. Unfortunately, Lp- PLA 2 inhibitor (darapladib) and s-PLA 2 inhibitor (varespladib methyl) failed to prove to lower the risk of composite CVD mortality, myocardial infarction and stroke in those with stable CVD and ACS. Herein, we describe the explanation based on the existing data why there is still a discrepancy among them. So, it highlights the opinion that phospholipase A 2 is merely the inflammation biomarkers of CVD risk and playing an important role ...
Source: Current Cardiology Reviews - Category: Cardiology Tags: Curr Cardiol Rev Source Type: research

Related Links:

In this study, there was no increased risk of adverse outcomes (including muscle aches, liver dysfunction, new onset of diabetes, cancer, and bleeding strokes), even when LDL was lowered to as low as 20 mg/dL. Although statin medications themselves have been linked to side effects, especially at high doses, it appears that extremely low LDL concentrations are not responsible for side effects. In other words, lowering LDL beyond our previous target of 70 mg/dL appears to be not only safe but beneficial, in patients with CVD. The post LDL cholesterol: How low can you (safely) go? appeared first on Harvard Health Blog.
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Drugs and Supplements Health Heart Health Source Type: blogs
We describe below the design of dal-GenE, a precision medicine, placebo-controlled clinical outcome trial of dalcetrapib in patients with a recent acute myocardial infarction with the unique feature of selecting only those with the AA genotype at rs1967309 in the ADCY9 gene.
Source: American Heart Journal - Category: Cardiology Source Type: research
Cardiovascular disease (CVD), such as heart attack and stroke, is a leading cause of death and disability in the US. High blood pressure and high cholesterol are major risk factors for CVD, and even though they are quite common and highly treatable, they tend to be undertreated. This is especially true among those who are poor or members of a minority. It’s estimated that thousands of lives could be saved each year if more people with high blood pressure and high cholesterol received treatment for these conditions. The appeal of the polypill One reason that high blood pressure and high cholesterol are poorly treated ...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Drugs and Supplements Health Heart Health Hypertension and Stroke Source Type: blogs
AbstractPurpose of the ReviewThis review highlights selected cardiovascular disease (CVD) prevention studies presented at the 2019 American Heart Association (AHA) Scientific Sessions.Recent FindingsSeveral important cardiovascular prevention studies were presented at the 2019 AHA Scientific Sessions. Results from the Colchicine Cardiovascular Outcomes Trial (COLCOT) showed that low-dose colchicine reduces the risk of recurrent CVD events among patients with recent myocardial infarction. A prospective analysis from the UK Biobank cohort demonstrated that the increased CVD risk associated with clonal hematopoiesis of indete...
Source: Current Atherosclerosis Reports - Category: Cardiology Source Type: research
ConclusionConsumers and health care providers need to recognize critical differences between Rx and OM-3 dietary supplements to ensure appropriate use of each OM-3 product.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Authors: Khan AA, Thomas GN, Lip GYH, Shantsila A Abstract Atrial fibrillation is the most common heart arrhythmia and is associated with poor outcomes. The adverse effects of atrial fibrillation are mediated through multiple pathways, including endothelial dysfunction, as measured by flow-mediated dilatation. Flow-mediated dilatation has demonstrated endothelial dysfunction in several conditions and is associated with poor outcomes including mortality, yet can be improved with medical therapy. It is thus a useful tool in assessing endothelial function in patients.Endothelial dysfunction is present in patients with...
Source: Annals of Medicine - Category: Internal Medicine Tags: Ann Med Source Type: research
Did you ever wonder why medical research seems to flip-flop so often? Eggs used to be terrible for your health; now they’re not so bad. Stomach ulcers were thought to be due to stress and a “type A personality” but that’s been disproven. I was taught that every postmenopausal woman should take hormone replacement therapy to prevent heart disease and bone loss; now it’s considered way too risky. It can make you question every bit of medical news you hear. But maybe that’s not such a bad thing. Questioning what you read or hear is reasonable. And maybe medical reversals — when new re...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Medical Research Prevention Tests and procedures Source Type: blogs
CONCLUSIONS: Intervention response heterogeneity was significant for nonfatal MI. Response heterogeneity may need consideration in a CVD-outcome trial design. PMID: 31898874 [PubMed - as supplied by publisher]
Source: Obesity - Category: Eating Disorders & Weight Management Authors: Tags: Obesity (Silver Spring) Source Type: research
ConclusionThe combination of LR and RF-based classifier performs better. This combination will be very helpful for predicting diabetic patients.
Source: Health Information Science and Systems - Category: Information Technology Source Type: research
The objective of this study was to investigate whether statins confer a beneficial effect on AF after AMI. Data available in the Taiwan National Health Insurance Research Database on 32886 AMI patients between 2008 and 2011 were retrospectively analyzed. Total 27553 (83.8%) had complete 1-yr follow-up data. Cardiovascular outcomes were analyzed based on the baseline characteristics and AF type (existing, new-onset, or non-AF). AF groups had significantly higher incidence of heart failure (HF), stroke, all-cause death, and major adverse cardiac and cerebrovascular event (MACCE) after index AMI (all P 
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Heart | Heart Attack | Hospitals | Stroke | Study